PR Newswire Asia's news > Medical/Pharmaceuticals

 < Previous page   |   Title only   |   Print    Next page > 
     
Datasea's AI Agent Digital Marketing Services Enter Scaled Commercial Deployment, with Five Agreements Representing Potential Annualized Service Volume of Up to Approximately US$89.4 Million (RMB600 Million)
Five-customer AI agent services advance into actual delivery; CEO reiterates long-term confidence through a previously disclosed US$1.0 million Rule 10b5-1 share purchase plan ...
2026-09-17T    Computer Software   Computer/Electronics   Internet Technology   Medical/Pharmaceuticals 
New Peer-Reviewed Study Confirms Innovative Technology Shatters ESR's Four-Hour Deadline
ALCOR Scientific's iSED® analyzers reshape lab logistics and improve patient care for one of medicine's most widely used tests ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
ZEISS expands retinal imaging portfolio with new ZEISS ALTA DUO 300
ZEISS' new multimodal solution combines automated OCT and fundus imaging to support simplified and efficient retinal assessment across a broader range of eye care practices. ...
2026-09-17T    Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
There's No One-Size-Fits-All for Treating Older Adults with Cancer, According to New NCCN Patient Resource
New guideline for patients and caregivers explains the importance of assessments to tailor cancer care to every person, regardless of age. ...
2026-09-17T    Health Care/Hospital   Medical/Pharmaceuticals 
Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR
— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
111 Inc. Receives Unsolicited Preliminary Non-Binding Proposal to Acquire the Company
SHANGHAI , Sept. 17, 2026 /PRNewswire/ -- 111 Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, today announced that its Board ...
2026-09-17T    Health Care/Hospital   Medical/Pharmaceuticals   Retail 
WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development
SHANGHAI , Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs
22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
111, Inc. Announces Second Quarter 2026 Unaudited Financial Results
Transition from An Asset-Heavy Business Model to An Asset-Light Business Model Ongoing Investment and Adoption of AI Agents Making Workforce Streamlining Possible Net Revenue of Promotional Products ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals   Multimedia/Online/Internet 
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
HONG KONG , Sept. 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate ...
2026-09-17T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.